Nordic Pharma Expands LACRIFILL Availability
The ocular treatment is now available in 2,200 medical practices across the United States to assist in dry eye management.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Do you trust new medical treatments to effectively manage your personal eye health?
Nordic Pharma has expanded the distribution of its LACRIFILL Canalicular Gel to 2,200 medical practices nationwide. The company, a subsidiary of SEVER Life Sciences B.V., released patient survey data regarding the treatment during the American Academy of Ophthalmology annual meeting.
Why it matters
The move aims to establish a broader market presence for the company in the sectors of dry eye management and post-surgical care. By providing an alternative to conventional eye drops, the gel seeks to improve comfort outcomes for a wide range of patients.
Nordic Pharma currently reports 130,000 total patients treated with the gel, which is indicated for up to six months of use. The expansion reaches 2,200 U.S. ophthalmology and optometry practices.
The players
Nordic Pharma
This company is a subsidiary of SEVER Life Sciences B.V. and specializes in products for dry eye management.
American Academy of Ophthalmology
This professional organization hosts annual meetings where experts share clinical research and medical industry advancements.
The details
Administered by medical professionals, the gel serves as a supplement or alternative to standard eye drops for patients dealing with ocular discomfort. Data presented at the American Academy of Ophthalmology shows that 96% of cataract surgery patients and 83% of general surgical patients reported improved comfort following the treatment.
Timeline
October 2026: Nordic Pharma reported the expansion and survey data.
Market Landscape
The expansion follows industry patterns showcased at the American Academy of Ophthalmology annual meeting. This move positions Nordic Pharma to capture greater market share in the competitive ophthalmology device sector.
Patients seeking alternatives to traditional eye drops may find this treatment available at their local ophthalmology or optometry office. Those undergoing cataract surgery may discuss the potential for reduced ocular discomfort with their healthcare providers.
The takeaway
Patients experiencing chronic dry eye or post-surgical irritation should consult with their eye care specialist to determine if this gel is an appropriate treatment. Understanding the distinction between medicated drops and canalicular gels can help individuals better manage their ocular health routines.
Further reading
Learn more about the latest innovations in United States Healthcare.
More information
For more details on the treatment, visit the LACRIFILL product information page.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust new medical treatments to effectively manage your personal eye health?
